Navigation Links
More than one-third of Texas women still receive unnecessary breast biopsy surgery
Date:5/17/2013

Many women in Texas who are found to have an abnormality on routine mammogram or discover a lump in one of their breasts end up having an old-fashioned surgical biopsy to find out whether the breast abnormality is malignant. Since 2001, national expert panels have recommended that the first course of action for women with breast lumps or masses should be minimally invasive biopsy.

Minimally invasive biopsies are most commonly done under ultrasonographic or X-ray guidance, with either a fine needle or preferably a "core tissue extraction" needle. They do not require surgery or anesthesia and leave little to no scarring. Most importantly, a diagnosis of benign (non-cancerous) or malignant (cancerous) breast mass can be determined before any decisions about treatment are made.

In spite of these benefits, new research from the University of Texas Medical Branch published in the Journal of the American College of Surgeons shows that expensive, invasive surgical breast biopsies remained the first diagnostic step for 35 percent of women diagnosed with a breast mass between 2000 and 2008 in Texas. The investigators performed an exhaustive analysis of Texas Medicare data from 2000 to 2008, including more than 87,000 breast biopsies.

The traditional method of removing the mass through surgery to obtain a definitive diagnosis has a number of negative consequences. If the mass is benign, then the woman had surgery unnecessarily; in fact, only 40 percent of the women studied ended up having breast malignancies. Simply put, thousands of women throughout Texas underwent surgery just to find out they did not have cancer.

On the other hand, if the mass is malignant, more surgery will probably be required to remove more tissue, so the patient will end up having to have multiple surgeries instead of only one. Surgery is far more expensive than needle biopsy, so for the Medicare patients in this study who underwent biopsy surgery, the government had to pay a much steeper tab.

"There is no benefit to the patient in having an expensive, invasive surgical procedure instead of a needle biopsy," said senior author Dr. Taylor Riall, UTMB associate professor of surgery and a lead investigator for the study. "We need to get the word out to women across the state that surgery is not the procedure of choice for definitive diagnosis of a breast mass."

The American Society of Breast Surgeons, the American College of Radiology and the National Cancer Center Network have all endorsed minimally invasive breast biopsy as providing results that are as accurate as surgical biopsies.

"At UTMB, minimally invasive biopsies are our diagnostic procedure of choice. We do them more than 98 percent of the time," said Riall.

The National Cancer Center Network is trying to find out what barriers stand in the way of reaching a 90 percent rate of minimally invasive breast biopsies nationwide. The study is a step in providing crucial information that will help in the national effort.


'/>"/>

Contact: Molly J. Dannenmaier
mjdannen@utmb.edu
409-771-5105
University of Texas Medical Branch at Galveston
Source:Eurekalert

Related medicine news :

1. Only one-third of parents follow doctors orders for kids all of the time
2. Nearly One-Third of Kids With Food Allergies May Be Bullied
3. Streetcar tracks blamed in one-third of Toronto bike accidents
4. Surgical patient safety program lowers SSIs by one-third following colorectal operations
5. One-Third of U.S. Homeless Population Is Obese: Study
6. One-third of adult Americans with arthritis battle anxiety or depression
7. Texas Health Insurance and California Health Insurance Quotes Now Available Online by Ace Health
8. Viewpoints TV Announces May Air Dates for the Dallas-Ft. Worth, Texas Area
9. Best 2013 Texas Home Security System Companies Graded by 6Webs.com
10. Texas teen appears in new video from the International Essential Tremor Foundation
11. Texas-Based Window Company Raising Money for Children's Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... Las Vegas Skin and Cancer Clinic (LVSCC) ... Friday, March 10, 2017, 4-7 pm PST. For more than six decades, LVSCC has ... the South Rancho neighborhood, has been renovated to provide medical and cosmetic dermatological products ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... healthcare automation intelligence company based in New York. , “Ensuring an intuitive, user-friendly ... workflow remains unaltered. Those two fundamental reasons are the reasons this acquisition is ...
(Date:2/28/2017)... ... 2017 , ... The role of females in the military, ... civilian life. Body image dissatisfaction is largely unexamined among female veterans, a rapidly ... of chronic mental health conditions than female civilians. Female veterans also are more ...
(Date:2/27/2017)... ... 27, 2017 , ... Bo Chen, PhD is the recipient of the 2017 ... during the Plenary Session at ASLMS 2017, the Annual Conference of the American Society ... April 5-9, 2017. , During the Plenary Session on April 7, Dr. Chen ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... the alternative health care industry, announces Chris Brandl as its New Guest Director. ... vision and purpose to corporations throughout his career. He began his professional career ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... 27, 2017 Amarantus ... BioMedical assets for potential acquisition ... contemplates capital infusion into Amarantus to assist in restructuring ... Amarantus names four new appointees to its Board of Directors and names ... Biomedical Inc. (SeD Biomedical) , a Singapore ...
(Date:2/28/2017)... The global  pulse oximeters market  is expected to reach USD 2.8 billion by ... oximeters market is anticipated to witness significant growth during the forecast period, which ... obstructive pulmonary disease (COPD), sleep apnea, cardiac arrhythmia, and ischemic conditions. ... ... Grand View Research Logo ...
(Date:2/28/2017)... 28, 2017 Nordic Nanovector ASA (OSE: NANO) announces ... presentation of the results by the company,s senior management team will ... - details below. ... 2016 was a very successful year for Nordic Nanovector. ... Betalutin®, progressed with our preclinical candidates and build the foundation of ...
Breaking Medicine Technology: